



Frank M. Brunkhorst, MD, PhD

WELCOME!

„An extracorporeal adsorption of inflammatory mediators, vasoactive peptides, bacterial toxins and nucleid acids may have a beneficial effect on immunoreactivity and consequently on the condition of patients with organ failure.

The CytoSorb® adsorber, a CE approved medical device for extracorporeal blood purification, is most promising for such an effect. Randomized clinical trials are ongoing. In parallel, we want to study the use of the adsorber in clinical routine, because many intensive care physicians already apply this medical device on their ICUs or in the OR. For this reason, the International CytoSorb Registry aims at assessing clinical effectiveness of this therapy under routine conditions by use of scientific methods.

That's why we would be glad if all CytoSorb users around the world took part in the International CytoSorb Registry and help us obtain representative results!“

Frank M. Brunkhorst, MD, PhD
Jena University Hospital, Center for Clinical Studies

Why joining the CytoSorb Registry?

- You are interested in extracorporeal adsorption methods
- You want to optimize your therapy
- You want to exchange your experiences with colleagues from all over the world
- Little effort: No intervention, no randomization
- Easy, quick and secure data entry using OpenClinica®
- Highest quality standard due to independent scientific supervision

Become now part of the International CytoSorb Registry!

Register here, it's done in 30 seconds:

www.cytosorb-registry.org

or with the QR code below



Universitätsklinikum
Jena University Hospital

Center for Clinical Studies



Benefit from the new tool for optimizing extracorporeal adsorption!

ClinicalTrials.gov
ID: NCT02312024

OVERVIEW

Why a registry?

Clinical registries are essential for long-term systematical assessment of benefits and safety of medical applications under routine conditions. Due to the patient group's heterogeneity, subgroups can be identified more easily and risk-benefit-profiles can be assessed in a more differentiated way compared to randomized controlled trials.

Inclusion criteria

Population:

Patients ≥ 18 years who undergo treatment with a CytoSorb adsorber

No minimum number of patients per center required!

Indications:


- Severe sepsis, septic shock
- Cardiac surgery with CPB
 - Preemptive use of CytoSorb in OR
 - Postoperative use of CytoSorb on ICU
- Others (e.g. liver failure, acute pancreatitis, trauma, burns)

Endpoints

Primary: Difference between mortality predicted by scoring systems (APACHE II / SAPS II, Euro SCORE II) and actual mortality within 30 days

Secondary: E.g. organ function, biomarkers, length of stay (ICU, hospital), duration of mechanical ventilation, of renal replacement therapy and of vasopressor therapy

HOW IT WORKS



Good to know!

The team at the Center for Clinical Studies (ZKS) Jena is looking forward to supporting you. In case of questions we are happy to be at your disposal anytime.

Contact us

Jena University Hospital
Center for Clinical Studies
07740 Jena, Germany
zks@med.uni-jena.de
Tel: +49 36 41 9 39 66 55

BENEFIT

Great benefit vs. little effort

Use the international data base provided by the CytoSorb Registry as an effective and versatile tool:

- **Treatment safety:** Be able to better reason your medical decisions.
- **Feedback:** Every 6 months you get detailed analyses of all registry data. You can compare your own therapy outcomes with other centers from all over the world in an anonymized way. If requested, individual interim analyses can be done.
- **Quality:** Results generated from the registry will help to optimize your future use of CytoSorb.
- **Publications:** You get various opportunities for publication of your results.



It takes only
30
minutes!

- Data required for the registry is recorded in clinical routine anyway. Each patient has to be followed up at 5 time points, time needed for the complete documentation is around 30 minutes.
- Electronic Data Capture (EDC) and Clinical Data Management (CDM) is done with renowned OpenClinica®. Data safety is of utmost priority for us!